Oryzon Genomics S.A. (0RDB.L)
EUR 1.6
(-4.88%)
EUR 1.6
(-4.88%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -634.75 Thousand | -1.97 Million | -4.12 Million | -5.88 Million | -4.41 Million | -763.07 Thousand |
| Net Income | -3.7 Million | -4.53 Million | -5.33 Million | -4.15 Million | -4.13 Million | -1.34 Million |
| Depreciation & Amortization | 168.78 Thousand | 156.96 Thousand | 151.53 Thousand | 162 Thousand | 155.08 Thousand | 159.51 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 403.36 Thousand | 411.32 Thousand | 1.05 Million | 183.93 Thousand | -431.74 Thousand | -639.6 Thousand |
| Other non-cash items | 2.49 Million | 1.98 Million | 5262.92 | -2.07 Million | -2876.05 | 1.06 Million |
| Investing Cash Flow | -16.01 Million | -15.28 Million | -13.34 Million | -11.09 Million | -10.74 Million | -7.99 Million |
| Investments in PPE | - | -80.94 Thousand | -199.61 Thousand | -186.51 Thousand | -129.36 Thousand | -194.33 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -16.01 Million | -15.2 Million | -13.14 Million | -10.9 Million | -10.61 Million | -7.79 Million |
| Financing Cash Flow | 6.64 Million | 9.32 Million | 4.69 Million | 22.45 Million | 15.99 Million | 8.03 Million |
| Debt repayment | -5.58 Million | -736.49 Thousand | -4.69 Million | -244.92 Thousand | -4.61 Million | -5.65 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -1.98 Million | -1.07 Million | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 14.22 Million | 9.66 Million | 4.12 Million | 22.2 Million | 20.61 Million | 13.68 Million |
| Accounts receivables | 371.33 Thousand | 307.4 Thousand | -125.04 Thousand | 192.4 Thousand | -361.32 Thousand | -131.36 Thousand |
| Accounts payables | - | -0.30 | - | -0.50 | - | - |
| Inventory | 4160.96 | 100.65 Thousand | 242.47 Thousand | -34.23 Thousand | -173.08 Thousand | -145.75 Thousand |
| Other working capital | 27.87 Thousand | 3272.30 | 932.86 Thousand | 25.76 Thousand | 102.66 Thousand | -362.48 Thousand |
| Cash at beginning of period | 22.82 Million | 32.69 Million | 48.38 Million | 39.38 Million | 39.31 Million | 41.93 Million |
| Cash at end of period | 13.53 Million | 22.82 Million | 32.69 Million | 48.38 Million | 39.38 Million | 39.31 Million |
| Capital Expenditure | - | -80.94 Thousand | -199.61 Thousand | -186.51 Thousand | -129.36 Thousand | -194.33 Thousand |
| Effect of forex changes on cash | -2897.99 | 1162.87 | 395.68 Thousand | 13.68 Thousand | 44.99 Thousand | - |
| Net cash flow / Change in cash | -9.29 Million | -9.86 Million | -15.68 Million | 8.99 Million | 67.39 Thousand | -2.61 Million |
| Free Cash Flow | -634.75 Thousand | -2.05 Million | -4.32 Million | -6.07 Million | -4.54 Million | -957.4 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 124.48 Thousand | -1.23 Million | -1.9 Million | -3.7 Million | -1.12 Million | 1.15 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | - | - | - |
| Other non-cash items | -124.48 Thousand | 1.23 Million | 1.9 Million | 3.7 Million | 1.12 Million | -1.15 Million |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | - | - | - | 22.82 Million | - | - |
| Cash at end of period | - | - | - | 22.82 Million | - | - |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
VSTM
AVY
HUQVF
ROCL
INDOSTAR
DOOH